
Nammi Therapeutics, Inc. is a pre-clinical stage biotech company focused on optimizing cancer immunotherapy by using nanocarriers to deliver synergistic anti-tumor and immune activating agents to the tumor.
Market:
Nammi Therapeutics products offer broad potential for efficacy across many solid tumor indications, thus providing a robust market opportunity in the multi-billion dollar range, while they are expected to reduce the cost of treating cancer through lower cost of goods and reduced cost of managing treatment related toxicities.Technology:
Nammi's technology utilizes nanocarriers to deliver synergistic anti-tumor and immunomodulatory combinations to the tumor microenvironment. An immunogenic cell death inducing chemotherapy primes the cancer site for recruitment of cytotoxic T cells in solid tumors. The response is sustained and synergistically enhanced by co-delivery of an immune adjuvant. The combined effect represents a unique mechanism of action providing a robust, systemic anti-tumor immune response, which can eliminate primary and metastatic disease, with immune memory.Advantages:
- Reduces off-target toxicity and provides greater efficacy
- Provides optimal immunotherapy combinations in a single therapy
- Lower cost to patients and reduced hospital costs due to lower toxicity
- Current therapies only work in a minority of solid tumor patients
Development Stage:
- Pre-clinical
Patents Issued:
- PCT/US20 18/033265: NANO-ENABLED IMMUNOTHERAPY IN CANCER (18 May 2017)
Select Publications:
- Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway | ACS Nano
- Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression | Nature Communications
Contact:
Email: info@nammiRX.comPhone: 424-901-6696
Website: www.nammiRX.com
Graduated in 2023
Graduated Companies
- Adaptix
- Aneeve
- Aneuvo
- Appia Bio
- Bluefin Foods
- Carbonics
- Charlot Biosciences
- CBD Research Institute
- Cellmic
- Concrete-AI
- Craytex
- CytoLumina
- DARTS Sciences
- Electronucleics
- EP Dynamics
- Ferrologix
- Horizon PV
- Inspira
- Inston
- InvVax
- Kelvi
- Keyssa
- Kythera Biopharmaceuticals
- Librede
- Lucendi
- Matrix Sensors, Inc.
- MAX BioPharma
- MediSens Wireless
- MicrobeDx
- Millibatt
- MyoGene Bio
- Myst Therapeutics
- Nammi Therapeutics
- NanoClear
- NanoElectronic Imaging
- NanoH₂O
- Nanopixel Technologies
- National Institute of Cannabinoid Research (NICR)
- Octant
- Omega Biosystems
- Orchard Therapeutics
- Polyradiant
- Qwixel Therapeutics
- Sardona Therapeutics
- SELFA
- Sixal
- Spectradyne Particle Analysis
- Tempo Therapeutics
- TrueCath
- U-Defi
- Valerion Therapeutics
- Vivibaba
- Zenomics
- Back to Portfolio